Background: LiverSTAT (LST) is a new blood test for MASLD stratification.
Aims: To retrospectively compare the efficacy of two combinations in one-step approach with two combinations: LST&LSM versus FIB-4&LSM, for the identification of advanced fibrosis (F3F4) in a multicenter multiethnic meta-dataset of MASLD patients.
Methods: Retrospective data from 5 hepatology centers from MASLD patients that underwent liver biopsy (LB) along with LSM, FIB-4 and LST. Efficiency has been assessed using concordance rates, number needed to screen (NNS) on subject with LB F3F4.
Results: Data from 786 patients (22%US, 39%Asia, 39%EU) was analyzed [age 57.1years, female 54.5%, BMI 31.4, ALT 52U/L]. LB prevalence of F3F4 was 32.8%.In the overall cohort, LB confirmed F3F4 among concordant LST&LSM and FIB-4&LSM, respectively, in 107/142(75%) vs 54/64(84.4%) with a screening efficiency (NNS) of 1.8 vs 2.2; the combination LST&LSM correctly identified twice more F3F4 patients than FIB-4&LSM.In the subgroup with LB≥20mm, LB confirmed F3F4 among concordant LST&LSM and FIB-4&LSM in 43/50(86%) vs 30/33(90%), NNS 1.6 and 1.8, respectively; the combination LST&LSM correctly identified 43% more F3F4 patients than FIB-4&LSM.DFP rate was higher with FIB4-&LSM than with LST&LSM (11.3% vs. 7%).
Conclusion: The combination LST&LSM outperforms FIB-4&LSM for the identification of MASH advanced fibrosis F3F4.
N. Alkhouri: Advisory Panel; Madrigal Pharmaceuticals, Inc., 89bio, Inc. Speaker's Bureau; Alexion Pharmaceuticals, Inc., Gilead Sciences, Inc. Advisory Panel; Altimmune Inc. Consultant; Boehringer-Ingelheim. Advisory Panel; Novo Nordisk. R. Nadeem: None. P. Leff: None. P. Mantry: None. R. Quiambao: Other Relationship; Fibronostics US Inc. J. Dupuy: None. M. Munteanu: Employee; Fibronostics. V. De Ledinghen: Advisory Panel; Fibronostics.
